Drugs in Dev. Neurology
Phase II
Spain 
Lead Product(s) : Leriglitazone
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Leriglitazone Meets Primary Endpoint in NEXUS Trial for Pediatric Cerebral Adrenoleukodystrophy
Details : MIN-102 (leriglitazone) is a novel oral selective PPAR gamma agonist with a potential first and best-in-class profile for CNS diseases, currently being investigated for cerebral Adrenoleukodystrophy.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 11, 2024
Lead Product(s) : Leriglitazone
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vafidemstat
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Eighteen MS patients were enrolled in this Phase II randomized, double-blind, placebo-controlled, parallel group, dose-finding trial that evaluated the safety and tolerability of two vafidemstat doses in relapse-remitting MS or secondary progressive MS p...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 13, 2021
Lead Product(s) : Vafidemstat
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vafidemstat
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : By modulating the histone modifying enzyme LSD1, vafidemstat has been shown to have potential in Alzheimer’s and a range of other CNS diseases.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 03, 2021
Lead Product(s) : Vafidemstat
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ACT-01 is a peptidomimetic first-in-class disease-modifying treatment for multiple sclerosis (MS) and acute optic neuritis, the latter with orphan drug designation by the US FDA and the EMA in the EU.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 03, 2021
Lead Product(s) : Leriglitazone
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Phase 2 NEXUS trial aims at evaluating the safety and efficacy of leriglitazone in pediatric patients with early-stage cerebral ALD (cALD), the acute form of X-linked adrenoleukodystrophy (X-ALD).
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 05, 2020
Lead Product(s) : Leriglitazone
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Leriglitazone
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 27, 2020
Lead Product(s) : Leriglitazone
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vafidemstat
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ORYZON Presents Efficacy Data From its Two Vafidemstat Clinical Trials in Alzheimer’s Disease
Details : REIMAGINE-AD is a Phase IIa study to assess the effect of vafidemstat in agitation-aggression in moderate and severe AD patients.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 04, 2020
Lead Product(s) : Vafidemstat
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vafidemstat
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Alzheimer's Drug Discovery Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 07, 2019
Lead Product(s) : Vafidemstat
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Alzheimer's Drug Discovery Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients With a-MCI or Vm-AD
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 12, 2018
Lead Product(s) : Albumin
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Grifols International
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
August 19, 2016
Lead Product(s) : Albumin
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Grifols International
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
